NEWS RELEASE

Teijin Nakashima Medical to Acquire
Otsuka Group Company’s Spine and Trauma BusinessTokyo, Japan, October 29, 2021 --- Teijin Nakashima Medical Co., Ltd., a Teijin Groupcompany that develops, manufactures and distributes artificial joints, spinal devices andtrauma devices, announced today that it has agreed to acquire and take over the spineand trauma (fracture) business of KiSCO Co., Ltd., owned by Otsuka Group‘s Otsuka
Medical Devices Co., Ltd.. Teijin Nakashima Medical will assume spine and trauma(fracture) business of KiSCO on the 1st day of February 2022.
KiSCO's proprietary products include expandable interbody fusion PEEK cage, aspine-fusion cage system, and a posterior support plate for fixing posterolateral bonefragments. The company also has highly skilled human resources specializing inorthopedics.
Teijin Nakashima Medical, supported by the addition of KiSCO’s specialty personneland products, will target sales of JPY 10 billion by 2025, with a focus on the increasing
demand for orthopedic implants in today’s aging societies. In particular, Teijin
Nakashima Medical expects to grow sales at a rate that exceeds the pace of theimplantable medical device market’s expansion, and also to strengthen its research anddevelopment capabilities.

Expandable interbody fusion
PEEK cageposterior support plate for fixing
posterolateral bone fragments

About KiSCO Co., Ltd.
Company name
KiSCO Co., Ltd.
Headquarters
Chuo-ku, Kobe-shi, Hyogo Prefecture
Establishment
September 14, 1968
CapitalJPY 1,932.06 million
President
Representative Director Ayumu Nakaji
Employees
91 (as of April 1, 2021)
Developing, manufacturing, import and sales of medicalBusinessdevice

KiSCO has been developing and selling implant products such as spinal fixationmaterials and osteosynthesis materials as a subsidiary of Otsuka Medical Device since
2011.
Teijin has been steadily expanding its commercial involvement with implantable medicaldevices. Teijin Nakashima Medical joined the Teijin group through a capital tie-up with
Nakashima Holdings in 2015. In 2018, Teijin Nakashima Medical acquired the spine
business of Century Medical, Inc., an importer and distributer of medical devices. Teijinalso established Teijin Medical Technologies to develop and distribute absorbent
bone-connecting material.
Teijin's healthcare business supports people in all stages of life. Through its growing
business with implantable medical devices, Teijin look forward to increasingly
enhancing the quality of life for people worldwide.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company thatsupports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD9.5 billion) in the fiscal year that ended on March 31, 2021.
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp